Procept Bio Robotics Corp PRCT
We take great care to ensure that the data presented and summarized in this overview for PROCEPT BioRobotics Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRCT
View all-
Cpmg Inc Dallas, TX5.33MShares$363 Million100.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.25MShares$289 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.29MShares$224 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.94MShares$200 Million0.09% of portfolio
-
Alliancebernstein L.P. New York, NY1.99MShares$135 Million0.04% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.57MShares$107 Million0.46% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.47MShares$99.9 Million0.01% of portfolio
-
Loomis Sayles & CO L P1.35MShares$92 Million0.09% of portfolio
-
Wellington Management Group LLP Boston, MA1.12MShares$76 Million0.01% of portfolio
-
State Street Corp Boston, MA1.07MShares$72.7 Million0.0% of portfolio
Latest Institutional Activity in PRCT
Top Purchases
Top Sells
About PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Insider Transactions at PRCT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 03
2024
|
Antal Rohit Desai |
SELL
Other acquisition or disposition
|
Indirect |
1,785,127
-38.73%
|
-
|
|
May 03
2024
|
R Kent Mc Gaughy Jr |
SELL
Other acquisition or disposition
|
Indirect |
1,785,127
-38.73%
|
-
|
|
May 03
2024
|
Alaleh Nouri EVP, CLO, CORP. SEC. |
SELL
Open market or private sale
|
Direct |
30,432
-7.27%
|
$1,886,784
$62.47 P/Share
|
|
May 03
2024
|
Alaleh Nouri EVP, CLO, CORP. SEC. |
BUY
Exercise of conversion of derivative security
|
Direct |
30,432
+9.65%
|
$152,160
$5.67 P/Share
|
|
May 01
2024
|
Thomas M Krummel Director |
SELL
Open market or private sale
|
Direct |
20,000
-30.47%
|
$1,200,000
$60.0 P/Share
|
|
Apr 18
2024
|
Larry L Wood Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,054
+50.0%
|
-
|
|
Mar 18
2024
|
Alaleh Nouri EVP, CLO, CORP. SEC. |
SELL
Open market or private sale
|
Direct |
441
-0.7%
|
$21,168
$48.83 P/Share
|
|
Mar 18
2024
|
Reza Zadno President, CEO |
SELL
Open market or private sale
|
Direct |
5,391
-2.19%
|
$258,768
$48.83 P/Share
|
|
Mar 18
2024
|
Kevin Waters EVP, CFO |
SELL
Open market or private sale
|
Direct |
1,024
-0.99%
|
$49,152
$48.83 P/Share
|
|
Mar 18
2024
|
Hisham Shiblaq EVP, Chief Comm. Officer |
SELL
Open market or private sale
|
Direct |
244
-0.43%
|
$11,712
$48.83 P/Share
|
|
Mar 15
2024
|
Kevin Waters EVP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
53,757
+22.17%
|
$215,028
$4.54 P/Share
|
|
Mar 06
2024
|
Hisham Shiblaq EVP, Chief Comm. Officer |
SELL
Open market or private sale
|
Direct |
1,759
-3.04%
|
$80,914
$46.67 P/Share
|
|
Mar 06
2024
|
Hisham Shiblaq EVP, Chief Comm. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,449
+31.37%
|
-
|
|
Mar 06
2024
|
Reza Zadno President, CEO |
SELL
Open market or private sale
|
Direct |
9,179
-3.59%
|
$422,234
$46.67 P/Share
|
|
Mar 06
2024
|
Reza Zadno President, CEO |
BUY
Grant, award, or other acquisition
|
Direct |
54,933
+17.67%
|
-
|
|
Mar 06
2024
|
Kevin Waters EVP, CFO |
SELL
Open market or private sale
|
Direct |
3,435
-6.5%
|
$158,010
$46.67 P/Share
|
|
Mar 06
2024
|
Kevin Waters EVP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
19,328
+26.78%
|
-
|
|
Mar 06
2024
|
Alaleh Nouri EVP, CLO, CORP. SEC. |
SELL
Open market or private sale
|
Direct |
2,749
-4.19%
|
$126,454
$46.67 P/Share
|
|
Mar 06
2024
|
Alaleh Nouri EVP, CLO, CORP. SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
18,311
+21.81%
|
-
|
|
Mar 04
2024
|
Thomas M Krummel Director |
SELL
Open market or private sale
|
Direct |
20,000
-12.44%
|
$960,000
$48.6 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 144K shares |
|---|---|
| Exercise of conversion of derivative security | 310K shares |
| Other acquisition or disposition | 3.57M shares |
|---|---|
| Open market or private sale | 442K shares |